PFS2 benefit with nivolumab plus ipilimumab versus chemotherapy was observed in the tumor PD-L1 ≥ 1% (HR 0.56; 95% CI, 0.33–0.94) and tumor PD-L1 < 1% (HR 0.52; 95% CI, 0.29–0.93) populations (Supplementary Fig. 2). The gene discussed is CD274; the disease is neoplasm.